This article is more than 5 years old. Information may no longer be current.

Ten important updates in hematologic malignancies

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

HemOnc Today presents 10 advances in the treatment of leukemia, lymphoma, myeloma and myeloproliferative neoplasms that may be relevant to your practice and help improve patient care.

• The FDA approved inotuzumab ozogamicin (Besponsa; Wyeth Pharmaceuticals, Pfizer) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Read more.
• CD19-specific chimeric antigen receptor-modified T-cell therapy induced durable molecular remissions in patients with high-risk chronic lymphocytic leukemia who failed previous treatment with ibrutinib (Imbruvica; Pharmacyclics, Janssen). Read more.
• The FDA granted priority review to brentuximab vedotin (Adcetris, Seattle Genetics) — an antibody-drug conjugate directed to CD30 — for the treatment of cutaneous T-cell lymphoma. Read more.
• Maintenance therapy with lenalidomide (Revlimid, Celgene) following autologous hematopoietic stem cell transplantation reduced mortality rates by 25% compared with placebo or observation among patients with newly diagnosed multiple myeloma. Read more.
• The FDA granted orphan drug designation to H3B-8800 (H3 Biomedicine, Eisai) — a potent, selective and orally bioavailable small molecule modulator of wild-type and mutant splicing factor 3b complexes — for the treatment of patients with acute myeloid leukemia and chronic myelomonocytic leukemia. Read more.
• GP2013 (Sandoz), a biosimilar to rituximab (Rituxan; Genentech, Biogen), demonstrated similar safety and efficacy as its reference agent in patients with previously untreated, advanced follicular lymphoma. Read more.
• The FDA approved CPX-351 (Vyxeos, Jazz Pharmaceuticals) — a liposome-encapsulated combination of daunorubicin and cytarabine — for two types of poor-prognosis acute myeloid leukemia. Read more.
• The FDA granted priority review to acalabrutinib (ACP-196, AstraZeneca), a highly selective, potent Bruton’s tyrosine kinase inhibitor, for the treatment of patients with previously treated mantle cell lymphoma. Read more.
• The FDA approved enasidenib (Idhifa; Celgene, Agios) — an oral targeted inhibitor of the IDH2 enzyme — for the treatment of adults with relapsed or refractory acute myeloid leukemia with an IDH2 mutation as detected by an FDA-approved test. Read more.
• The FDA granted breakthrough therapy designation to acalabrutinib for the treatment of patients with mantle cell lymphoma who received at least one prior therapy. Read more.